Legend Capital co-leads $293m round in Chinese Diagnostics Medical Corp

An automated machine works on purification of potential hepatitis C virus drug candidate at the Gilead Sciences Inc. lab in Foster City, California, U.S., on Wednesday, Feb. 8, 2012. Photographer: David Paul Morris/Bloomberg

Legend Capital, the venture and growth capital arm of China’s Legend Holdings Ltd, has co-led an RMB2 billion ($293 million) investment in Chinese Diagnostics Medical Corporation by joining China Renaissance’s healthcare fund, China Money Network reported.

Continue reading this story with a subscription to DealStreetAsia.


Contact us for corporate subscriptions at subs@dealstreetasia.com.